Table 6.
Percentage of participants with clinically significant response rate and symptom remission rate as assessed with the clinician-rated measures of depression and anxiety+a.
| Measure | Group | Assessment time-point |
|||||
|---|---|---|---|---|---|---|---|
| Post-session 1 | Post-session 2 | 6 monthsb | |||||
| Clinical response | Symptom remission | Clinical response | Symptom remission | Clinical response | Symptom remission | ||
| GRID-HAMD-17 (Depression) | Low-Dose-1st (High-Dose-2nd) | 32% | 16% | 75% | 58% | 77% | 59% |
| High-Dose-1st (Low-Dose-2nd) | 92%*** | 60%** | 84% | 68% | 79% | 71% | |
| HAM-A (Anxiety) | Low-Dose-1st (High-Dose-2nd) | 24% | 12% | 83% | 42% | 82% | 50% |
| High-Dose-1st (Low-Dose-2nd) | 76%*** | 52%** | 80% | 60% | 83% | 63% | |
Data are percentage of participants fulfilling criteria at Post-session 1 (5 weeks after Session 1), Post-session 2 (5 weeks after Session 2), and 6 months. Clinical response was defined as ⩾50% decrease in measure relative to Baseline; Symptom remission was defined as ⩾50% decrease in measure relative to Baseline and a score of ⩽7 on GRID-HAMD-17 or HAM-A. For the Post-session 1, Post-session 2, and 6-month time-points, respectively, the number of participants was 25, 24, and 22 in the Low-Dose-1st (High-Dose-2nd) Group, and 25, 25, and 24 in the High-Dose-1st (Low-Dose-2nd) Group.
Within each data column, asterisks indicate significant differences between groups (*p<0.05, **p<0.01, ***p<0.001, planned comparisons, z-tests).
Effects of psilocybin on response and remission were sustained at 6 months as indicated by an absence of significant difference (p>0.05, planned comparisons, z-tests) between (1) Post-session 2 vs. 6 months in the Low-Dose-1st (High-Dose-2nd) Group and (2) Post-session 1 vs. 6 months in the High-Dose-1st (Low-Dose-2nd) Group. Overall response and remission rates were somewhat higher at 6 months when data were excluded for the six participants who initiated treatment with an antidepressant or anxiolytic between Post-session 2 and 6 months: on the GRID-HAMD-17 mean response and remission rate across the two dose sequence groups at 6 months increased from 78% to 83% and from 65% to 68%, respectively. On the HAM-A these rates increased from 83% to 85% and from 57% to 60%, respectively.